BOC RNA provides customized research and GMP-grade mRNA, with a flexible production scale from milligrams to grams to meet the various needs of researchers.
mRNA has been widely used in the study of gene function and is popular in the development of new therapeutic strategies for cancer immunotherapy and preventive vaccines. BOC RNA has been an industry leader in custom mRNA synthesis for research and clinical applications. Our service enables researchers to synthesize and introduce mRNA modifications to generate transcripts suitable for downstream applications.
In the central dogma, genetic information flows from DNA to mRNA (transcription process), and from mRNA to proteins that perform physiological functions (translation process). Following this idea, mRNA technology is to use biotechnology to synthesize mRNA in vitro and then introduce it into cells, and use the intracellular translation system to synthesize functional proteins, so that human cells themselves become factories for the production of target proteins, which can be applied to vaccines and protein replacement. therapy, tumor immunotherapy, gene editing and many other fields of biomedicine.
In the mRNA synthesis reaction, the synthesized mRNA must have the same characteristics as the endogenous mRNA in the cell. The stability and translation efficiency of the mRNA synthesized in vitro are enhanced by adding modified nucleotides, cap and tail structures to escape recognition by the natural immune system in the cell.
In vitro transcriptional (IVT) synthesis of mRNA is a cell-free system in vitro, using plasmid DNA as a template, using RNA polymerase to transcribe and synthesize mRNA, and then adding 5' caps and 3' poly (A) tails and other modifications to it to simulate in vivo mRNA process of synthesis. The in vitro transcription method allows for in vitro-transcribed mRNA (IVT mRNA) of 10 kb or more in length and rapid expression of the target gene upon entry into the target cell.
With high promoter specificity, it activates transcription of DNA located downstream of the T7 promoter and synthesizes mRNA approximately 5-fold faster than the RNA polymerase of common E. coli. T7 RNA polymerase also has promoter-specific transcriptional activity in vitro and is the first single-subunit RNA polymerase identified to be overexpressed in E. coli for the construction of in vitro transcription systems.
T7RNAP has both DNA-template- and RNA-template-dependent RNA polymerase activity and can recognise conserved promoter sequences with a high degree of specificity, but its polymerase activity has a very large scale of flexibility. Whether the double-stranded DNA promoter sequence is followed by a DNA sequence, RNA sequence, or a chemeric DNA-RNA, T7RNAP can initiate transcriptional synthesis of RNA sequences, which can be seen as T7RNAP's promoter-dependent polymerase activity.
One study used RNA-Seq to study the sequence and yield distribution of in vitro transcription reaction products and found that the end of the RNA product in the IVT reaction can fold back to form a hairpin structure, turning itself into a primer, and that the addition of NTPs at the 3'-end produces RNA in excess of the expected length product, and that as the concentration of RNA product increases, this process competes with the normal transcription process that uses DNA as a template This process competes with the normal transcription process using DNA as the template. The above process can be regarded as a polymerase activity reaction that is independent of the promoter sequence. This process can be cyclical, resulting in the longer RNA product dominating the IVT reaction instead.
BOC RNA is equipped with various scales of automatic synthesizers, advanced purification equipment, and has a wealth of mRNA synthesis experience. We have prepared a complete set of mRNA synthesis and purification technology to provide high-quality mRNA products. All products are produced under strict quality control standards and are identified by mass spectrometry and purified by HPLC.
BOC RNA also provides expert support in the design, production and evaluation of mRNA vaccines. Contact us to tell us more about your needs. The expertise of our scientists, engineers and support team are at your disposal!
GMP Oligonucleotide Manufacturing Service
For more than 15 years, BOC Sciences has been manufacturing oligonucleotides for pre-clinical, pharmaceutical, food safety, and animal health industries. We provide customized and flexible oligonucleotide GMP or non-GMP production services to meet different production needs.
Lipid Nanoparticle(LNP) for RNA Delivery
BOC Sciences offers comprehensive LNP- mRNA delivery services tailored to meet the specific needs of mRNA vaccine development. Our expertise in nanoparticle formulation and mRNA chemistry enables us to design custom LNP formulations optimized for stability, efficacy, and safety.
BOC Sciences promises to offer you with GalNAc-siRNA conjugation services to help you conduct further research on GalNAc-siRNA conjugates and explore their mores omnics capabilities, the working mechanism as well as their potential therapeutic profiles.
BOC Sciences offers aptamer customization services to generate high-quality aptamers tailored to your goals, delivering excellent results even for the most difficult target molecules.
Peptide-Oligonucleotide Conjugation
BOC Sciences is committed to providing our customers with comprehensive modification and labeling, offering affordable custom oligonucleotides or peptide-oligonucleotide conjugates.